- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07871851
Investigation of the Effectiveness of Spinal Stabilization Exercises Added to Aerobic Exercise in Women With Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a multisystemic disorder with metabolic and endocrine implications, commonly observed in women of reproductive age and characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Insulin resistance, chronic low-grade inflammation, hormonal imbalances, and obesity can contribute to reduced cardiorespiratory fitness and muscular endurance, in addition to the metabolic complications associated with PCOS. Furthermore, psychosocial effects such as depression, anxiety, and impaired quality of life may also occur. Lifestyle modifications and exercise are among the first-line approaches in the management of PCOS. Aerobic and resistance exercises have been reported to have positive effects on insulin resistance, cardiometabolic risk factors, hormonal profiles, inflammation, body composition, and reproductive functions. However, evidence regarding the specific effects of different exercise modalities on physical fitness components-such as cardiovascular and muscular endurance, which are adversely affected in PCOS-remains limited. Spinal stabilization exercises constitute an exercise approach aimed at enhancing core muscle strength and endurance, postural control, and movement quality by targeting deep trunk muscle activation, lumbopelvic stability, and neuromuscular control. Although studies exist regarding Pilates interventions targeting the core region in individuals with PCOS, no study has been found that examines the effects of spinal stabilization exercises administered either in isolation or as an adjunct to aerobic exercise. Therefore, it is hypothesized that incorporating spinal stabilization exercises into an aerobic exercise regimen may provide additional benefits-particularly regarding metabolic, hormonal, and inflammatory outcomes, alongside physical fitness components.
The aim of this study is to comparatively examine the effects of spinal stabilization exercises added to aerobic exercise-versus aerobic exercise alone-on metabolic, hormonal, and inflammatory markers, anthropometric characteristics, cardiovascular fitness, core muscle strength and endurance, and quality of life in individuals with PCOS.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Polycystic ovary syndrome (PCOS) is a common multisystem endocrine and metabolic disorder among women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. In addition to reproductive disturbances, PCOS is associated with insulin resistance, chronic low-grade inflammation, hormonal imbalances, obesity, and an increased risk of long-term metabolic complications. These alterations may also negatively affect physical fitness, particularly cardiorespiratory fitness and muscular endurance. Furthermore, PCOS may be accompanied by psychosocial problems, including depression and anxiety, which may contribute to impaired quality of life.
Lifestyle interventions, particularly physical activity and exercise, are considered first-line strategies in the management of PCOS. Aerobic and resistance exercise have been shown to improve insulin resistance, cardiometabolic risk factors, hormonal profiles, inflammation, body composition, and reproductive outcomes. However, evidence regarding their effects on physical fitness components that may be impaired in PCOS, particularly cardiorespiratory fitness and muscular endurance, remains limited. Moreover, there is no clear consensus regarding the specific effectiveness of different exercise modalities, contents, and training volumes on physical fitness outcomes in women with PCOS.
Spinal stabilization exercises focus on activating the deep trunk muscles and improving lumbopelvic stability, neuromuscular control, core muscle strength and endurance, postural control, and movement quality. Considering the adverse effects of insulin resistance, chronic inflammation, and hormonal disturbances on muscle morphology and physical fitness in PCOS, spinal stabilization exercises may provide additional benefits in this population. Although Pilates-based interventions targeting the core region have demonstrated beneficial effects on quality of life, hormonal profiles, menstrual symptoms, and certain physical fitness parameters in women with PCOS, the effects of spinal stabilization exercises, either alone or in combination with aerobic exercise, have not yet been investigated in this population. Therefore, adding spinal stabilization exercises to aerobic exercise may provide additional benefits for metabolic and hormonal functions, body composition, cardiorespiratory fitness, and muscular endurance.
The aim of this study is to compare the effects of aerobic exercise combined with spinal stabilization exercises versus aerobic exercise alone on metabolic, hormonal, and inflammatory markers, anthropometric parameters, cardiorespiratory fitness, core muscle strength, core muscle endurance, and quality of life in individuals with PCOS.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Malatya
-
Malatya, Malatya, Turquie (Türkiye), 44280
- Inönü University Department of Obstetrics and Gynecology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Individuals aged 18-45 years (premenopausal) diagnosed with PCOS by an obstetrician-gynecologist, with a body mass index between 25 and 39.9 kg/m² and a physical activity level below 600 MET-min/week (inactive) according to the International Physical Activity Questionnaire-Short Form (IPAQ-SF) assessment.
Exclusion Criteria:
- Pregnancy, diabetes, smoking, participation in a dietary intervention, congenital adrenal hyperplasia, thyroid diseases, hyperprolactinemia, Cushing's syndrome, or musculoskeletal disorders preventing exercise; use of antihypertensive medications, insulin-sensitizing drugs, nutritional supplements, or weight-loss medications
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: aerobic exercise group
|
The aerobic training group will undergo aerobic exercise on a treadmill three days a week for eight weeks under the supervision of a specialist physiotherapist. For patients with no prior treadmill experience, the first session will serve as a trial session to facilitate adaptation to the treadmill. In subsequent sessions, the aerobic training will be conducted in phases comprising warm-up, exertion, and cool-down periods. |
|
Expérimental: spinal stabilization exercise group combined with aerobic exercise
|
The aerobic training group will undergo aerobic exercise on a treadmill three days a week for eight weeks under the supervision of a specialist physiotherapist. For patients with no prior treadmill experience, the first session will serve as a trial session to facilitate adaptation to the treadmill. In subsequent sessions, the aerobic training will be conducted in phases comprising warm-up, exertion, and cool-down periods. As a first step in spinal stabilization training, individuals will be instructed on proper postural alignment. To determine each individual's ideal posture, a neutral spine position-characterized by comfort and a lack of pain in the lumbopelvic region-will be identified in front of a mirror, and the contraction of deep muscles (abdominal bracing) will be taught. Individuals will be required to maintain proper posture and deep muscle group activation throughout the exercises. Stretching and mobility exercises targeting the lumbar region, trunk muscles, and lower extremities will be performed for approximately 5-10 minutes as part of the warm-up and cool-down periods surrounding the spinal stabilization exercises. The exercises will be conducted for approximately 30 minutes. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fasting Blood Glucose Concentration
Délai: At baseline and after 8 weeks of treatment
|
Fasting blood glucose concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL. |
At baseline and after 8 weeks of treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fasting Serum Insulin Concentration
Délai: At baseline and after 8 weeks of treatment
|
Fasting serum insulin concentration will be measured from venous blood samples after an overnight fast and reported in µIU/mL. |
At baseline and after 8 weeks of treatment
|
|
Fasting Serum Triglyceride Concentration
Délai: At baseline and after 8 weeks of treatment
|
Fasting serum triglyceride concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL. |
At baseline and after 8 weeks of treatment
|
|
Serum High-Density Lipoprotein Cholesterol Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum high-density lipoprotein cholesterol (HDL-C) concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL. |
At baseline and after 8 weeks of treatment
|
|
Serum Low-Density Lipoprotein Cholesterol Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum low-density lipoprotein cholesterol concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL. |
At baseline and after 8 weeks of treatment
|
|
Serum Total Cholesterol Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum total cholesterol concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL. |
At baseline and after 8 weeks of treatment
|
|
Serum Prolactin Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum prolactin concentration will be measured from venous blood samples after an overnight fast and reported in ng/mL. |
At baseline and after 8 weeks of treatment
|
|
Serum Luteinizing Hormone Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum luteinizing hormone concentration will be measured from venous blood samples after an overnight fast and reported in mIU/mL. |
At baseline and after 8 weeks of treatment
|
|
Serum Follicle-Stimulating Hormone Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum follicle-stimulating hormone concentration will be measured from venous blood samples after an overnight fast and reported in mIU/mL. |
At baseline and after 8 weeks of treatment
|
|
Serum Thyroid-Stimulating Hormone Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum thyroid-stimulating hormone concentration will be measured from venous blood samples after an overnight fast and reported in µIU/mL. |
At baseline and after 8 weeks of treatment
|
|
Serum High-Sensitivity C-Reactive Protein Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum high-sensitivity C-reactive protein concentration will be measured from venous blood samples after an overnight fast and reported in mg/L. |
At baseline and after 8 weeks of treatment
|
|
Free Androgen Index
Délai: At baseline and after 8 weeks of treatment
|
Free androgen index will be calculated using total testosterone and sex hormone-binding globulin concentrations and reported as a dimensionless value. |
At baseline and after 8 weeks of treatment
|
|
Serum Estradiol Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum estradiol concentration will be measured from venous blood samples after an overnight fast and reported in pg/mL. |
At baseline and after 8 weeks of treatment
|
|
Serum Sex Hormone-Binding Globulin Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum sex hormone-binding globulin concentration will be measured from venous blood samples after an overnight fast and reported in nmol/L. |
At baseline and after 8 weeks of treatment
|
|
Serum Anti-Müllerian Hormone Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum anti-Müllerian hormone concentration will be measured from venous blood samples after an overnight fast and reported in ng/mL. |
At baseline and after 8 weeks of treatment
|
|
Homeostatic Model Assessment of Insulin Resistance
Délai: At baseline and after 8 weeks of treatment
|
Insulin resistance will be calculated using fasting glucose and fasting insulin concentrations according to the Homeostatic Model Assessment of Insulin Resistance formula and reported as an index value. |
At baseline and after 8 weeks of treatment
|
|
Serum Interleukin-6 Concentration
Délai: At baseline and after 8 weeks of treatment
|
Serum interleukin-6 concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL. |
At baseline and after 8 weeks of treatment
|
|
Serum Interleukin-10 Concentration
Délai: At baseline and 8 weeks after treatment.
|
Serum interleukin-10 concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL. |
At baseline and 8 weeks after treatment.
|
|
Serum Tumor Necrosis Factor-Alpha Concentration
Délai: At baseline and 8 weeks after treatment.
|
Serum tumor necrosis factor-alpha concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL. |
At baseline and 8 weeks after treatment.
|
|
Serum Adiponectin Concentration
Délai: At baseline and 8 weeks after treatment.
|
Serum adiponectin concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in ng/mL. |
At baseline and 8 weeks after treatment.
|
|
Serum Irisin Concentration.
Délai: At baseline and 8 weeks after treatment.
|
Serum irisin concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in ng/mL. |
At baseline and 8 weeks after treatment.
|
|
Waist-to-Hip Ratio
Délai: At baseline and 8 weeks after treatment
|
Waist circumference and hip circumference will be measured in meters (m). The waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference. |
At baseline and 8 weeks after treatment
|
|
Waist-to-Height Ratio
Délai: At baseline and 8 weeks after treatment
|
Waist circumference and height will be measured in meters (m). The waist-to-height ratio will be calculated by dividing waist circumference by height. |
At baseline and 8 weeks after treatment
|
|
Anthropometric Measurement (Body Mass Index)
Délai: At baseline and 8 weeks after treatment
|
Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m². |
At baseline and 8 weeks after treatment
|
|
Body Weight Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Body weight will be measured using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg). |
At baseline and 8 weeks after treatment
|
|
Body Fat Mass Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Body fat mass will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg). |
At baseline and 8 weeks after treatment
|
|
Body Fat Percentage Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Body fat percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%). |
At baseline and 8 weeks after treatment
|
|
Fat-Free Mass Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Fat-free mass will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg). |
At baseline and 8 weeks after treatment
|
|
Body Muscle Percentage Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Body muscle percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%). |
At baseline and 8 weeks after treatment
|
|
Total Body Water Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Total body water will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg). |
At baseline and 8 weeks after treatment
|
|
Total Body Water Percentage Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Total body water percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%). |
At baseline and 8 weeks after treatment
|
|
Visceral Fat Rating Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment
|
Visceral fat will be assessed using a Tanita bioelectrical impedance analysis device and reported as the visceral fat rating provided by the device. |
At baseline and 8 weeks after treatment
|
|
Cardiovascular fitness (6-minute walk test)
Délai: At baseline and 8 weeks after treatment
|
Cardiovascular fitness will be assessed using the 6-Minute Walk Test. Participants will be instructed to walk along a 30-meter corridor for 6 minutes at their usual walking pace. The total distance walked during 6 minutes will be recorded in meters (m). |
At baseline and 8 weeks after treatment
|
|
Core muscle endurance (trunk flexor test)
Délai: At baseline and 8 weeks after treatment
|
Trunk flexor endurance will be assessed using the McGill Trunk Flexor Test. Participants will maintain the standardized trunk flexion position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s). |
At baseline and 8 weeks after treatment
|
|
Core muscle endurance (trunk extensor test)
Délai: At baseline and 8 weeks after treatment
|
Trunk extensor endurance will be assessed using the McGill Trunk Extensor Test. Participants will maintain the standardized horizontal trunk position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s). |
At baseline and 8 weeks after treatment
|
|
Core muscle endurance (side bridge test)
Délai: At baseline and after 8 weeks of treatment
|
Lateral trunk muscle endurance will be assessed using the Side Bridge Test. Participants will maintain the standardized side bridge position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s). |
At baseline and after 8 weeks of treatment
|
|
Core muscle strength (sit-up test)
Délai: At baseline and after 8 weeks of treatment
|
Core muscle strength will be assessed using the 30-second Sit-Up Test. Participants will perform as many sit-ups as possible within 30 seconds. The total number of correctly completed repetitions will be recorded. |
At baseline and after 8 weeks of treatment
|
|
Core muscle strength (Modified Push-up test)
Délai: At baseline and after 8 weeks of treatment
|
Core muscle strength will be assessed using the 30-second Modified Push-Up Test. Participants will perform as many modified push-ups as possible within 30 seconds. The total number of correctly completed repetitions will be recorded. |
At baseline and after 8 weeks of treatment
|
|
Polycystic Ovary Syndrome Quality of Life-50 Scale
Délai: At baseline and after 8 weeks of treatment
|
Quality of life will be assessed using the Polycystic Ovary Syndrome Quality of Life-50 Scale. The scale consists of 50 items across six domains: psychosocial and emotional status, fertility, sexual function, obesity and menstrual disorders, hirsutism, and coping with the disease. Each item is scored from 1 to 5, with a total score ranging from 50 to 250. Higher total scores indicate better quality of life. |
At baseline and after 8 weeks of treatment
|
|
Patient's Perception of Global Change
Délai: After 8 weeks of treatment
|
Participants' perceived change in polycystic ovary syndrome-related symptoms compared with baseline will be assessed using the Global Perceived Improvement Scale. The scale ranges from 1 to 7: 1 = very much better, 2 = much better, 3 = slightly better, 4 = no change, 5 = slightly worse, 6 = much worse, and 7 = very much worse. Lower scores indicate greater perceived improvement, whereas higher scores indicate greater perceived worsening. |
After 8 weeks of treatment
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Maladies du système endocrinien
- Processus pathologiques
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies génitales, femme
- Maladies ovariennes
- Maladies annexielles
- Troubles gonadiques
- Kystes de l'ovaire
- Kystes
- Conditions pathologiques, signes et symptômes
- Inflammation
- Syndrome des ovaires polykystiques
- Activité motrice
- Mouvement
- Phénomènes physiologiques musculo-squelettiques
- Phénomènes physiologiques musculo-squelettiques et neuronaux
- Exercice
Autres numéros d'identification d'étude
- 2026-06/15
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .